DOCSLIB.ORG

ACT UP, 268-271, 298 Adenylate Cyclase, See Adenylyl Cyclase

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ACT UP, 268-271, 298 Adenylate Cyclase, See Adenylyl Cyclase ACT UP, 268-271, 298 adenylate cyclase, see adenylyl cyclase adenylyl cyclase ibogaine potentiation of morphine effect on,7 ibogaine potentiation of serotonin effect on,12, 146 mu-opioid inhibition of, 98-99 Adriaans, Nico Dutch Junkiebond and, 253, 283-284 Dutch Addict Self-Help (DASH) and, 283-4, 298, 302, 311 Erasmus University and, 258-259, 271, 298 view on importance of peer counseling in ibogaine treatment, 290 acetylcholine, EEG and, 9, 28-29 muscarinic acetylcholine receptors, iboga alkaloids and, 9, 41, 50 nicotinic acetylcholine receptors, iboga alkaloids and, 6, 9-10, 41, 50-51 REM sleep and, 29 affinity of iboga alkaloids at various receptor sites, tables, 41, 81, 167 anomie, 238 anxiety cocaine withdrawal and, 146-148 ibogaine and, 227-234 kappa-opioid receptors and, 231-232 Bastiaans, Jan, Dr. ibogaine treatments in the Netherlands, and, 260, 285, 298 LSD and, 260 Beal, Dana (see also Cures-not-Wars), 271-272 benzodiazepine receptor, 179 binding, space and time, iboga and, 239, 244 Bin-Wahad, Dhoruba, 272 Bwiti estimated dosages of iboga alkaloids used, table, 242 sacramental use of iboga, 30, 235-247, 294 work of the ancestors, iboga and, 239, 245 cannabis, market separation from hard drugs, 270 cardiovascular effects, iboga alkaloids, 25, 49, 166-167 cerebellar Purkinje cells, climbing fiber synapses originating from the inferior olive, excitoxicity and, 12, 184-185 charismatic group, 30 Chemical Abstracts ibogamine skeleton numbering, 3, (see A Note Concerning the Numbering of Iboga Alkaloids) Christiana, Copenhagen, 261-263 civil disobedience, 267 Clouet, Doris, Dr., 252-253 Cocaine cardiovascular effects of ibogaine and 166 dopamine efflux in the rat NAc, iboga alkaloids and, 15-16 dopamine efflux in mouse brain slice, ibogaine and effect of kappa-opioid antagonist, 8 EEG effects of ibogaine and, 196-200 locomotor response to, iboga alkaloids and, 46-47, 51 self- administration, iboga alkaloids and 5, 12-13, 16, 22, 42,45-46, 48, 119, 127- 129 sensitization, 15-16, 47-48 stereotypy and, 46-47 withdrawal anxiety, ibogaine and, 146-148 colonialism 30, 237-40 corticosterone secretion rat, ibogaine and, 200-201 rat, ibogaine and noribogaine and, 100-103 craving, drug animal model, 220-221 measurement in humans utilizing the Heroin Craving Questionnaire (HCQ-29), 163, 165 effects on with ibogaine in humans, 16-17, 165-169, 284, 287 Cures-not-Wars, 264, 272, 275 cytochrome P450 2D6 (CYPD2D6), 82-83, 158-161 Czech Republic, ibogaine scene in, 264-265 DASH (Dutch Addict Self-Help), 253, 257-58 Doors of Perception, The, 251 dopamine brain tissue levels, effect of ibogaine on, 9, 87-91, 108, 199-202 efflux, NAc, cocaine, iboga alkaloids and, 15-16, 47-48 efflux, NAc, morphine, iboga alkaloids and 15, 45 efflux, NAc, nicotine, iboga alkaloids and 15-16, 47-48 receptor affinity, iboga alkaloids, 9, 41, transporter, iboga alkaloids and, 9, 86-87, 117 Dole, Vincent P. Dr., 290, 312 DOM (2,5-dimethoxy-4-methylamphetamine), 10, 63, 66-69, 71 Drug discrimination beta-carbolines in ibogaine-trained animals, 11, 69-71 fixed ratio schedule, 64 NMDA antagonists in ibogaine-trained animals, 11, 72 nonessential stimulus components, ibogaine, 10-11, 66-69 noribogaine in ibogaine-trained animals, 11, 74-75 opioids in ibogaine-trained animals, 73-74 serotonergic agents in ibogaine-trained animals, 8, 10-11, 66-69, 75 sigma ligands in ibogaine-trained animals, 74-75 dynorphin, ibogaine and, 11 ECoG (electrocortigogram) 194-200 EEG (electroencephalogram) ibogaine and, 9, 24, 28-29 effect of cocaine in rats pretreated with ibogaine 194-200 learning and, 29-30 ethanol self-administration, iboga alkaloids and, 12, 51, 127 Erasmus University, Rotterdam, 253-254, 257-259, 271, 298 eye movements, observations reported by treatment guides, 30 fatalities, 25-27 FDA (US Food and Drug Administration) approval of IND submitted by D. Mash, 5, 255, 303 scheduling of ibogaine, 4 fenfluramine, 8, 66, 92, 102, 201 fluoxetine, 11, 69 fluvoxamine, 69 focus group for participants in DASH treatments, 258, 284 Fluoro-Jade, cerebellar degeneration and, 23, 208 Frenken, Geerte, 257 Gabon 4, 253, 265, 294 GFAP (glial fibrillary acid protein), 22-23, 106, 203-204 gender differences bioavailability, 19-20, 84 kinetics and metabolism of ibogaine and noribogaine in rats, 84-85, 107-108 neuropathology, 22 visual phenomena related to ibogaine in humans, 256 Glick, Stanley, Dr., 253 glycine, 7, 58-59, 61 Goutarel, Robert, 29-30, 256, 275 guide, treatment, 17, 285-288, 300 hallucinations, 18-19, 286 haloperidol, sigma receptor and, 174, 176 harm reduction, 267-268, 270-272, 278, 290 harmaline 107, 174, 184-185, 188 Harms, Josien 257, 283 heroin self-administration, ibogaine and, 12-13 smoking, 26 withdrawal, human, ibogaine and 17, 155-172, 284-298, ibogaine chemical properties, 2-3 mechanisms of action, 6-10, 40-41, 49-51, 55-62, 115-133, 140-142, 167-169 opioid receptors and, 7-8, 41, 167-169 pharmacokinetics, see pharmacokinetics, ibogaine possible differences related to manufacturing source, 119 price, Slovenia, 261 scheduling, 4, 250-251, 268, 272 Ibogaine Mailing List 6, 262, 276 Ibogaine Story, The 264, 275 ICASH (International Coalition of Addict Self-Help) 5, 283, 298-299 INTASH (International Addict Self-Help) 235, 239-243, 254, 257, 283, 285-286, 290, 302 Internet, 6, 262, 264, 276-277 Isbell, Harris, Dr., 4 Junkiebond, Dutch, 253, 268, 270-271, 283 Kabouters, 269 Kaplan, Charles, Dr., 258-259, 284 Ka-Tzetnik 135633 (Yehiel De-Nur), 260 Kleber, Herbert, Dr. 284 Lambarène, 4, 115 LeMen and Taylor ibogamine skeleton numbering, 3, ( see A Note Concerning the Numbering of Iboga Alkaloids) Lieberman, Dan, 263, 265-266 locomotor activity cocaine, iboga alkaloids, and 14-15, 46-48, 91 morphine, iboga alkaloids and, 14-15, 44-45 stereotypy and, 15, 47 long-term outcomes, ibogaine treatments, 17-18, 156 Lotsof, Howard initial observations of ibogaine effect in humans, 4, 251-252, 294-295 patents for use of ibogaine in drug dependence and, 4-5, 253 NDA International and, 253-254 LSD (lysergic acid diethylamide) Jan Bastiaans and, 260 5HT2A receptor and, 66-69 Mash, Deborah, Dr., FDA and, 5, 166, 254-55 St. Kitts and, 17, 25, 155-171, 255 Memantine, 57, 59, 61 18-Methoxycoronaridine (18-MC) drug self-administration and, 13, 40-46, 48, 51 locomotor behavior and, 44-48 morphine withdrawal and, 40, 43-44, 47, 51 NMDA receptors and, 41,44-45, 49, 60-61 opioid receptors and, 41, 44-45, 49, 51 serotonin and, 41, 49, 51 sigma receptors and 41, 49, 79-83 morphine dopamine efflux in NAc, iboga alkaloids and 15, 45 locomotor response to, iboga alkaloids and, 14, 44 modulation of effects by ibogaine, 212 self-administration, iboga alkaloids and, 42-43, 213-214 withdrawal, animal, effect of iboga alkaloids, 13-14, 40, 43-44, 51, 98-99, 215- 219 mouse differences from the rat regarding ibogaine with regard to ibogaine effect on locomotor response to cocaine, 15 differences from the rat regarding ibogaine neurotoxic effects, 207-208 knockout, 117, 125, 128 morphine withdrawal and, 14 Naranjo, Claudio, Dr., 4, NDA International, 15, 251, 253-255, 259-260, 268, 298, 303 NDE (near death experience), 30-31 neurotensin-like immunoreactivity (NTLI), ibogaine and, 11 neurotoxicity human evidence 24-25 neuropathological studies in animals 22-24, 105-107, 202-209 sigma receptors and, 173-174, 176, 184-186, 188 NIAD (Netherlands Institute for Alcohol and Drugs) 259, 285 nicotine dopamine efflux, iboga alkaloids and, 10, 15-16, 45, 47 self-administration/ preference, iboga alkaloids and, 5, 12-13, 33, 42, 46 nicotinic acetylcholine receptor, see acetylcholine NIDA (National Institute on Drug Abuse), 2, 5 252-254, 259, 267, 269, 271-275, 278 NIDA Ibogaine Review Meeting, March 1995, 5, 17 NIH (National Institutes of Health), 273 NMDA (N-methyl-D-aspartate) affinity of ibogaine for the NMDA receptor 6-7, 41, 56-60, 81, 167 discriminative stimulus of ibogaine, and, 11, 72-73, effects of NMDA antagonists in opioid withdrawal 59 functional evidence for ibogaine as NMDA antagonist 7, 56-60, 184 18-MC and, 41,44-45, 49, 60-61 noribogaine and 41, 60, 81, 105, 167 sigma receptors and, 174-175, 184-185 norharman, effect on morphine withdrawal, 14 noribogaine (10-hydroxyibogamine) identification as a primary metabolite of ibogaine, 81-82, 157-158 NMDA receptors and 41, 60, 81, 105, 167 opioid receptors and, 7-8, 41, 81, 108, 167-169 serotonin receptor interactions, 41, 81, 167 serotonin release in NAc and, 47 sigma receptors and, 179-187 tissue dopamine levels and, 108 normalization, 252, 271 nucleus accumbens (NAc) core vs. shell regions, 12, 15-16 dopamine efflux in response to drugs, effects of iboga alkaloids, 15-16, 45, 47-48 olivocerebellar projection, 23, 184-185 oneiric/ oneirophrenic effects, 18, 275, 309 opioid receptors, interactions with iboga alkaloids, ibogaine 8, 41, 167-169 18-MC 41, 44-45, 49, 51 noribogaine 7-8, 41, 81, 108, 167-169 Parker, Jon, 24 panoramic memory, 18, 28, 30, 287-288, 299-301 pharmacokinetics, ibogaine animal pharmacokinetic studies 19-20, 81-85, 95, 161 gender and gonadectomy and, 84-85 heterogeneity among CYP isoforms, 20, 158-160, 162 humans, 19-20, 159-160 place preference amphetamine, ibogaine and, 220 morphine, ibogaine and, 220 plus maze, 146-148, 151, 229-232 political theater, tactics of, 269-271 prolactin secretion rat, effect of ibogaine 200-201 rat, effect of ibogaine and noribogaine 100-103 Provos, 269 reinstatement paradigm, 220 REM sleep 29-30 Resinovic, Marko, 260-261 Rock Against Racism, 272 runway paradigm, rewarding and aversive effects of
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 8,940,728 B2
    USOO894.0728B2 (12) UnitedO States Patent (10) Patent No.: US 8,940,728 B2 Mash et al. (45) Date of Patent: Jan. 27, 2015 (54) SUBSTITUTED NORIBOGAINE 5,152.994. A 10/1992 Lotsof 5,283,247 A 2f1994 Dwivedi et al. (71) Applicant: DemeRx, Inc., Miami, FL (US) 5,316,7595,290,784. A 3/19945/1994 Quetal.Rose et al. 5,382,657 A 1/1995 K. tal. (72) Inventors: Deborah C. Mash, Miami, FL (US); 5,426,112 A 6, 1995 ity a Richard D. Gless, Jr., Oakland, CA 5,552,406 A 9, 1996 Mendelson et al. (US); Robert M. Moriarty, Michiana 5,574,052 A 1 1/1996 Rose et al. Shores, IN (US) 5,578,645 A 11/1996 Askanazi et al. s 5,580,876 A 12/1996 Crain et al. 5,591,738 A 1, 1997 LotSof (73) Assignee: DemeRx, Inc., Miami, FL (US) 5,618,555 A 4/1997 Tokuda et al. - 5,703,101 A 12/1997 Rose et al. (*) Notice: Subject to any disclaimer, the term of this 5,726, 190 A 3, 1998 Rose et al. patent is extended or adjusted under 35 S.S.; A s 3. th. 1 U.S.C. 154(b)(b) bybV 144 davs.ayS 5,865.444.wwk A 2/1999 KempfetOSe et al. al. 5,925,634 A 7/1999 Olney (21) Appl. No.: 13/732,751 5,935,975 A 8/1999 Rose et al. 6,211,360 B1 4/2001 Glicket al. (22) Filed: Jan. 2, 2013 6,291.675 B1 9/2001 Coop et al.
    [Show full text]
  • The Alkaloids: Chemistry and Biology
    CONTRIBUTORS Numbers in parentheses indicate the pages on which the authors’ contributions begin. B. EMMANUEL AKINSHOLA (135), Department of Pharmacology, College of Medicine, Howard University, Washington, DC 20059, eakinshola@ howard.edu NORMA E. ALEXANDER (293), NDA International, 46 Oxford Place, Staten Island, NY 10301, [email protected] SYED F. ALI (79, 135), Division of Neurotoxicology, National Center for Toxicological Research, 3900 NCTR Road, Jefferson, AR 72079, [email protected] KENNETH R. ALPER (1, 249), Departments of Psychiatry and Neurology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, [email protected] MICHAEL H. BAUMANN (79), Clinical Psychopharmacology Section, Intra- mural Research Program, NIDA, National Institutes of Health, Baltimore, MD 21224, [email protected] DANA BEAL (249), Cures-not-Wars, 9 Bleecker Street, New York, NY 10012, [email protected] ZBIGNIEW K. BINIENDA (193), Division of Neurotoxicology, National Cen- ter for Toxicological Research, 3900 NCTR Road, Jefferson, AR 72079, [email protected] WAYNE D. BOWEN (173), Laboratory of Medicinal Chemistry, NIDDK, NIH, Building 8 B1-23, 8 Center Drive, MSC 0820, Bethesda, MD 20892, [email protected] FRANK R. ERVIN (155), Department of Psychiatry and Human Genetics, McGill University, Montreal, Quebec H3A 2T5, Canada, md18@musica. mcgill.ca JAMES W. FERNANDEZ (235), Department of Anthropology, University of Chicago, 1126 E. 59th Street, Chicago, IL 60637, jwfi@midway. uchicago.edu xi xii CONTRIBUTORS RENATE L. FERNANDEZ (235), Department of Anthropology, University of Chicago, 1126 E. 59th Street, Chicago, IL 60637, rlf2@midway. uchicago.edu GEERTE FRENKEN (283), INTASH, P.O.
    [Show full text]
  • Near the Himalayas, from Kashmir to Sikkim, at Altitudes the Catholic Inquisition, and the Traditional Use of These of up to 2700 Meters
    Year of edition: 2018 Authors of the text: Marc Aixalà & José Carlos Bouso Edition: Alex Verdaguer | Genís Oña | Kiko Castellanos Illustrations: Alba Teixidor EU Project: New Approaches in Harm Reduction Policies and Practices (NAHRPP) Special thanks to collaborators Alejandro Ponce (in Peyote report) and Eduardo Carchedi (in Kambó report). TECHNICAL REPORT ON PSYCHOACTIVE ETHNOBOTANICALS Volumes I - II - III ICEERS International Center for Ethnobotanical Education Research and Service INDEX SALVIA DIVINORUM 7 AMANITA MUSCARIA 13 DATURA STRAMONIUM 19 KRATOM 23 PEYOTE 29 BUFO ALVARIUS 37 PSILOCYBIN MUSHROOMS 43 IPOMOEA VIOLACEA 51 AYAHUASCA 57 IBOGA 67 KAMBÓ 73 SAN PEDRO 79 6 SALVIA DIVINORUM SALVIA DIVINORUM The effects of the Hierba Pastora have been used by Mazatec Indians since ancient times to treat diseases and for divinatory purposes. The psychoactive compound Salvia divinorum contains, Salvinorin A, is the most potent naturally occurring psychoactive substance known. BASIC INFO Ska Pastora has been used in divination and healing Salvia divinorum is a perennial plant native to the Maza- rituals, similar to psilocybin mushrooms. Maria Sabina tec areas of the Sierra Madre Oriental Mountains of Mexi- told Wasson and Hofmann (the discoverers of its Mazatec co. Its habitat is tropical forests, where it grows between usage) that Salvia divinorum was used in times when the- 300 and 800 meters above sea level. It belongs to the re was a shortage of mushrooms. Some sources that have Lamiaceae family, and is mainly reproduced by cuttings done later feldwork point out that the use of S. divinorum since it rarely produces seeds. may be more widespread than originally believed, even in times when mushrooms were abundant.
    [Show full text]
  • The Iboga Alkaloids
    The Iboga Alkaloids Catherine Lavaud and Georges Massiot Contents 1 Introduction ................................................................................. 90 2 Biosynthesis ................................................................................. 92 3 Structural Elucidation and Reactivity ...................................................... 93 4 New Molecules .............................................................................. 97 4.1 Monomers ............................................................................. 99 4.1.1 Ibogamine and Coronaridine Derivatives .................................... 99 4.1.2 3-Alkyl- or 3-Oxo-ibogamine/-coronaridine Derivatives . 102 4.1.3 5- and/or 6-Oxo-ibogamine/-coronaridine Derivatives ...................... 104 4.1.4 Rearranged Ibogamine/Coronaridine Alkaloids .. ........................... 105 4.1.5 Catharanthine and Pseudoeburnamonine Derivatives .. .. .. ... .. ... .. .. ... .. 106 4.1.6 Miscellaneous Representatives and Another Enigma . ..................... 107 4.2 Dimers ................................................................................. 108 4.2.1 Bisindoles with an Ibogamine Moiety ....................................... 110 4.2.2 Bisindoles with a Voacangine (10-Methoxy-coronaridine) Moiety ........ 111 4.2.3 Bisindoles with an Isovoacangine (11-Methoxy-coronaridine) Moiety . 111 4.2.4 Bisindoles with an Iboga-Indolenine or Rearranged Moiety ................ 116 4.2.5 Bisindoles with a Chippiine Moiety ... .....................................
    [Show full text]
  • A Quarter Century of Pharmacognostic Research on Panamanian Flora: a Review*
    Reviews 1189 A Quarter Century of Pharmacognostic Research on Panamanian Flora: A Review* Authors Catherina Caballero-George 1, Mahabir P. Gupta2 Affiliations 1 Institute of Scientific Research and High Technology Services (INDICASAT‑AIP), Panama, Republic of Panama 2 Center for Pharmacognostic Research on Panamanian Flora (CIFLORPAN), College of Pharmacy, University of Panama, Panama, Republic of Panama Key words Abstract with novel structures and/or interesting bioactive l" bioassays ! compounds. During the last quarter century, a to- l" Panamanian plants Panama is a unique terrestrial bridge of extreme tal of approximately 390 compounds from 86 l" ethnomedicine biological importance. It is one of the “hot spots” plants have been isolated, of which 160 are new l" novel compounds and occupies the fourth place among the 25 most to the literature. Most of the work reported here plant-rich countries in the world, with 13.4% en- has been the result of many international collabo- demic species. Panamanian plants have been rative efforts with scientists worldwide. From the screened for a wide range of biological activities: results presented, it is immediately obvious that as cytotoxic, brine shrimp-toxic, antiplasmodial, the Panamanian flora is still an untapped source antimicrobial, antiviral, antioxidant, immunosup- of new bioactive compounds. pressive, and antihypertensive agents. This re- view concentrates on ethnopharmacological uses Supporting information available at of medicinal plants employed by three Amerin- http://www.thieme-connect.de/ejournals/toc/ dian groups of Panama and on selected plants plantamedica Introduction are a major component of the Panamanian tropi- ! cal forest. Mosses abound in moist cloud forests as Medicinal plants remain an endless source of new well as other parts of the country.
    [Show full text]
  • Bio-Guided Search of Active Indole Alkaloids from Tabernaemontana
    Bioorganic Chemistry 85 (2019) 66–74 Contents lists available at ScienceDirect Bioorganic Chemistry journal homepage: www.elsevier.com/locate/bioorg Bio-guided search of active indole alkaloids from Tabernaemontana T catharinensis: Antitumour activity, toxicity in silico and molecular modelling studies Pauline Fagundes Rosalesa,b, Flavio Ferreira Marinhoa, Adriana Gowera, Marilda Chiarelloa, ⁎ Bianca Cancic, Mariana Roesch-Elyc, Favero Reisdorfer Paulad, Sidnei Mouraa, a Laboratory of Biotechnology of Natural and Synthetics Products, University of Caxias do Sul, Brazil b Federal Institute of Education, Science and Technology of Rio Grande do Sul, Campus Bento Gonçalves, Brazil c Laboratory of Genomics, Proteomics and DNA Repair, University of Caxias do Sul, Brazil d Laboratory of Research and Drugs Development, Federal University of Pampa, Brazil ARTICLE INFO ABSTRACT Keywords: Active plant metabolites have been used as prototype drugs. In this context, Tabernaemontana catharinensis Tabernaemontana catharinensis (Apocynaceae) has been highlighted because of the presence of active indole alkaloids. Thus, this study aims the A549 cell bio-guided search of T. catharinensis cytotoxic alkaloids. The chemical composition was identified by high-re- A375 cell solution mass spectrometry, and fractionation was performed by open column and preparative thin-layer Indole alkaloid chromatography, from plant stems. The enriched fractions were tested in vitro in tumour cells A375 (melanoma Toxicity cell line) and A549 (adenocarcinomic human alveolar basal epithelial cells), and non-tumour Vero cells (African green monkey kidney epithelial cells). The alkaloids identified as active were submitted to in silico toxicity prediction by ADME-Tox and OSIRIS programs and, also, to molecular docking, using topoisomerase I (PDB ID: 1SC7) by iGEMDOCK.
    [Show full text]
  • The Anti-Addiction Drug Ibogaine and the Heart: a Delicate Relation
    Molecules 2015, 20, 2208-2228; doi:10.3390/molecules20022208 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Review The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation Xaver Koenig * and Karlheinz Hilber * Department of Neurophysiology and Neuropharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstrasse 17, Vienna 1090, Austria * Authors to whom correspondence should be addressed; E-Mails: [email protected] (X.K.); [email protected] (K.H.); Tel.: +43-1-40160-31232 (X.K.); +43-1-40160-31230 (K.H.); Fax: +43-1-40160-931300 (X.K. & K.H.). Academic Editor: Patricia Valentao Received: 24 October 2014 / Accepted: 26 November 2014 / Published: 29 January 2015 Abstract: The plant indole alkaloid ibogaine has shown promising anti-addictive properties in animal studies. Ibogaine is also anti-addictive in humans as the drug alleviates drug craving and impedes relapse of drug use. Although not licensed as therapeutic drug and despite safety concerns, ibogaine is currently used as an anti-addiction medication in alternative medicine in dozens of clinics worldwide. In recent years, alarming reports of life-threatening complications and sudden death cases, temporally associated with the administration of ibogaine, have been accumulating. These adverse reactions were hypothesised to be associated with ibogaine’s propensity to induce cardiac arrhythmias. The aim of this review is to recapitulate the current knowledge about ibogaine’s effects on the heart and the cardiovascular system, and to assess the cardiac risks associated with the use of this drug in anti- addiction therapy. The actions of 18-methoxycoronaridine (18-MC), a less toxic ibogaine congener with anti-addictive properties, are also considered.
    [Show full text]
  • SOFT 1998 Meeting Abstracts.Pdf
    ABSTRACTS: SOFT-TIAFT 1998 Page I Editor's note: The numbers before each title refer to the number assigned in the 1998 SOFT/TIAFT meeting program. The material has been reformatted for this printing. El'ery effort has been made to maintain the accuracy ofthe abstracts. Joseph R. Monforte, Ph.D., DABFT, ToxTalk Editor 4: Safety Of Buprenorphine: Ceiling For Cardio-Respiratory And Subjective Effects At High IV Doses Marilyn A. Huestis, Annie Umbricht, Kenzie L. Preston, and Edward J. Cone, NIDA Intramural Research Program, 5500 Nathan Shock Dr., Baltimore, MD 21224. Buprenorphine (BUP), a partial 11 agonist and K antagonist, is under development for treatment of opioid dependence. The present study was conducted to test the safety and abuse potential of intravenous (IV) BUP in the range of doses used for maintenance treatment. Concerns have been raised about the potential acute health risk ofbuprenorphine if diverted and used by the IV route at doses equivalent to those used for maintenance. Subjective effects ofBUP SL (12 mg) and IV/SL placebo (in random order) and BUP IV (2, 4, 8, 12, and 16 mg in increasing dose order) were evaluated in separate sessions in this single-blind, double-dummy study. Data were collected from 6 non-dependent male opioid abusers. Safety parameters included continuous monitoring of vital signs and oxygen saturation for 3 h after drug administration and additional collections over the next 72 h. Subjective measures included visual analog scales of global drug effects, ARCI subscales, and adjective rating scales. An increase in Systolic Blood Pressure for the 8 mg IV dose (+ 13.5 mm Hg) as .~\ compared to placebo was the only statistically significant change in blood pressure, heart rate or oxygen saturation among the 7 drug conditions.
    [Show full text]
  • I Ml Llllllll Ill Illl Lll Lll Lllllllllllll Llll Llllll Ll~Lllll Ill1
    IMl llllllll Illillll lllll lllll lllllllllllllll llllllllllllllll ll~lllll Ill1 USOO5152994A United States Patent [I91 [II] Patent Number: 5,152,994 Lotsof 1451 Date of Patentz * Oct. 6, 1992 [54] RAPID METHOD FOR INTERRUPTING OR ATTENUATING POLY-DRUG OTHER PUBLICATIONS DEPENDENCY SYhmROMES “Effect of ibogaine on naloxone-precipitated with- [76] Inventor: Howard S. Lotsof, 46 Oxford PI., drawal syndrome in chronic morphine-dependent Staten Island, N.Y. 10301 rats”, Dzoljic et al, Arch. Int. Pharmacodyn Ther., 294, 64-70, 1988. [ l ] Notice: The portion of the term of this patent subsequent to Feb. 12,2002 has been Primaty Examiner-Thurman K. Page disclaimed. Assistant Examjner-Carlos Azpuru Attorney, Agent, or Firm-Howard C. Miskin [21] Appl. No.: S31,100 1571 ABSTRAtX [22] Filed: May 31,19!X! The administration to a poly-drug addict of ibogaine, [51] Int. Cl.5 .. .. .. .. AOlN 43/W, A6lK 31/55; ibogaine, tabernanthine, alkaloids in the family of A6lK 9/08; A6lK 9/48 apocynaceae, or their non-toxic salts have been discov- [52] U.S. Cl. .. .. .. ..a................424/43% 424/451; ered to interrupt the physiological and psychological 424/463; 424/464; 514/214; 514/810; 514/811; aspectsof poly-drug dependency (heroin, cocaine, alco- 514/812; 514/513 hol, nicotine, caffeine, amphetamine, desoxyephedrine [58] Field of Search . .. .. 514/810, 81 1, 812, 813, or methadone in combinations thereof). A single treat- 514/214; 424/401, 436,451,463, 464 ment or series of treatments may be effective for one to References Cited eighteen months or longer. Treatment consists of the 1561 oral or rectal administration of ibogaine, ibogamine, U.S.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,925,634 Olney (45) Date of Patent: *Jul
    USOO5925634A United States Patent (19) 11 Patent Number: 5,925,634 Olney (45) Date of Patent: *Jul. 20, 1999 54 USE OF IBOGAINE FOR TREATING Green, P.G., et al., “Antinociception opioids and the cholin NEUROPATHIC PAIN ergic system,” Progress in Neurobiology 26: 119-146 (1986). 75 Inventor: John W. Olney, Ladue, Mo. Harsing, L.G., et al., “Evidence that ibogaine releases dopamine from the cytoplasmic pool in isolated mouse 73 Assignee: Washington University, St. Louis, Mo. striatum.” J. Neural. Transm. Gen. Sect. 96: 215–25 (1994). Popik, P., et al., “The putative anti-addictive drug ibogaine * Notice: This patent is Subject to a terminal dis is a competitive inhibitor of H MK-801 binging to the claimer. NMD receptor complex, Psychopharmacology 114: 672–674 (1994). 21 Appl. No.: 08/854,979 Sershen, H., et al., “Ibogaine antagonizes cocaine-induced 22 Filed: May 13, 1997 locomotor stimulation in mice,” Life Sci 50: 1079–1086 (1992). Related U.S. Application Data Sershen, H., et al., “Ibogaine reduces preference for cocaine consumption in C57BL/6By mice,” Pharmacol Biochem 60 Division of application No. 08/398,731, Mar. 6, 1995, Pat. No. 5,629,307, which is a continuation-in-part of application Behav 47: 13–19 (1994). No. 07/877,839, May 1, 1992, which is a continuation-in Sershen, H., “Effect of ibogaine on Serotonergic and dopam part of application No. 07/467,139, Jan. 18, 1990, aban inergic interactions in Striatum from mice and rats, Neu doned, which is a continuation-in-part of application No. rochem. Res. 19: 1463-1464 (1994).
    [Show full text]
  • Radioligand Displacement) [Ki, (95% CI) in Nm] for Iboga Alkaloids at Mouse Opioid Receptors (N = 3
    Supplementary Tables Table S1: Binding affinities (Radioligand Displacement) [Ki, (95% CI) in nM] for iboga alkaloids at mouse opioid receptors (n = 3). Receptor Oxa-noribogaine Epi-oxa-noribogaine mMOR 86 (65; 115) 136 (111; 166) mKOR 36 (29; 44) 6.9 (5.7; 8.3) mDOR 168 (127; 223) 94 (85; 104) For radioligand experiments fitted curves were constrained to top = 100 and bottom = 0. Table S2: Agonist activity (GTPγS assay) [EC50, (95% CI) in nM], {%Emax} of iboga alkaloids at mouse opioid receptors (n ≥ 3). Receptor Oxa-noribogaine Epi-oxa-noribogaine mMOR 559 (331, 920) {101} 211 (139, 322) {111} mKOR 49 (37, 64) {92} 9.6 (7.2, 12.8) {89} mDOR 329 (91, 117) {100} 99 (75, 130) {108} Efficacy data were obtained using agonist induced stimulation of [35S]GTPγS binding assay. Efficacy is represented as EC50 (nM) and percent maximal stimulation (Emax) relative to standard agonist DAMGO (MOR), DPDPE (DOR), or U50,488 (KOR) at 1000 nM. Table S3: Agonist activity (G protein BRET assay) [EC50, (95% CI) in nM], {%Emax} of iboga alkaloids at human and rat opioid receptors (n = 3). Receptor U50,488 Noribogaine Oxa-noribogaine Epi-oxa-noribogaine hKOR 13 (8, 20) {100} 7,745 (284; 21,050) {46} 68 (42; 109) {108} 16 (10; 26) {96} rKOR 18 (11; 32) {100} 6,239 (2,657; 14,650) {54} 43 (17; 126) {78} 12 (7; 23) {77} Table S4: Noribogaine functional assays [EC50/IC50, (95% CI) in nM], {%Emax} (n = 1). Assay (Species) Receptor Noribogaine hKOR (Agonist) 8,325 (6143; 11,280) {73} GTPγS (human) h5-HT2A (Agonist) n.d.
    [Show full text]
  • TUTICORIN RAGHAVACHARI GOVINDACHARI (30 July 1915 - 28 December 2001)
    TUTICORIN RAGHAVACHARI GOVINDACHARI (30 July 1915 - 28 December 2001) Biog. Mems. Fell. INSA, New Delhi, 26, 123-158, (2004) TUTICORIN RAGHAVACHARI GOVINDACHARI (1915-2001) Elected Fellow 1959 UTICORIN RAGHAVACHARI GOVINDACHARI, widely known as TRG in Tscientific circles, was an internationally known Natural Products Chemist who had devoted his entire professional life to this pursuit. Apart from his profound scientific contributions to the investigation of Indian flora, he established several institutions of basic research. He was greatly loved and admired for his personal traits like deep erudition enriched by simplicity and gentleness. BIRTH, EARLY LIFE AND EDUCATION TRG was born on July 30, 1915 at Irulappa Street, George Town, Madras (now known as Chennai). His parents were TG Raghavachari and Rajalakshmi, orthodox but forward looking Aiyangars. The former was a lawyer by profession but had many interests and talents, most of which were inherited by TRG who also was heir to his mother's great love of gardening. TRG whose pet name in the family circle was Patta started his schooling at the Hindu Theological School in GeorgeTown, Madras and later studied in Pachiappa School. His college education was at the Loyola College (1930-1932, Intermediate) and then Presidency College (1932-1934, B.Sc. Chemistry). He was awarded the Wilson Medal in Chemistry for 1934. In keeping with his conservative background, he wore a tuft up to his college days. TRG was a bright student and a voracious reader who would cry even if he came second in class! Playing cricket and gilli-danda and flying kites with his friends were his childhood pastimes.
    [Show full text]